Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Yerramilli VS, Lin G, Reisinger JL, Hemmerlin RM, Lindberg SK, Plante K, Ross AH, Gericke A, Scarlata S. The scaffolding protein IQGAP1 enhances EGFR signaling by promoting oligomerization and preventing degradation. J Biol Chem. 2024 Nov; 300(11):107844.
-
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.
-
Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, J?nne PA, Mino-Kenudson M, Swanson S, Wright CD, Kozono D, Marcoux P, Piotrowska Z, Sequist LV, Willers H. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024 Jul 05; 29(7):609-618.
-
Bugide S, Edwards YJK, Gupta R, Green MR, Wajapeyee N. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proc Natl Acad Sci U S A. 2023 01 24; 120(4):e2218118120.
-
Kato T, Asakura T, Edwards CE, Dang H, Mikami Y, Okuda K, Chen G, Sun L, Gilmore RC, Hawkins P, De la Cruz G, Cooley MR, Bailey AB, Hewitt SM, Chertow DS, Borczuk AC, Salvatore S, Martinez FJ, Thorne LB, Askin FB, Ehre C, Randell SH, O'Neal WK, Baric RS, Boucher RC. Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. Am J Respir Crit Care Med. 2022 12 01; 206(11):1336-1352.
-
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).
-
Wu Q, Zhen Y, Shi L, Vu P, Greninger P, Adil R, Merritt J, Egan R, Wu MJ, Yin X, Ferrone CR, Deshpande V, Baiev I, Pinto CJ, McLoughlin DE, Walmsley CS, Stone JR, Gordan JD, Zhu AX, Juric D, Goyal L, Benes CH, Bardeesy N. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2022 05 02; 12(5):1378-1395.
-
White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer. 2022 05; 23(3):e210-e221.
-
B?uerle T, Gupta S, Zheng S, Seyler L, Leporati A, Marosfoi M, Maschauer S, Prante O, Caravan P, Bogdanov A. Multimodal Bone Metastasis-associated Epidermal Growth Factor Receptor Imaging in an Orthotopic Rat Model. Radiol Imaging Cancer. 2021 07; 3(4):e200069.
-
Cruz-Gordillo P, Honeywell ME, Harper NW, Leete T, Lee MJ. ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells. Sci Signal. 2020 11 17; 13(658).